Fennec Pharmaceuticals Inc (FENC) Smart Money Holdings (13F, Q2 2026)

FENC ranks #4397 out of 37696 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

FENC is a top-conviction position for Rosalind Advisors, Inc. — at 12.7% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

GAMMA Investing LLC has added to its FENC position for two straight quarters, increasing it by $4.4K to reach $4.9K today.

True Wealth Design, LLC has trimmed its FENC position for two straight quarters, cutting it by $15.0 while still holding $96.0.

FENC is down 2% today, but institutions show net buying of $33.0M this quarter — a divergence between today's price move and the underlying institutional flow.

FENC reported a net loss of $3.3M over the trailing twelve months.

• Not yet profitable — net loss of $3.3M over the trailing twelve months
• Revenue grew 77.8% year over year
• Net income improved year over year, from -$12.0M to -$3.3M
• Operating cash flow was negative, using $12.5M in cash
• Current ratio of 6.37x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.99x equity — within a conventional range